[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE60334250D1 - Erzeugung und isolierung antigenspezifischer t-zellen - Google Patents

Erzeugung und isolierung antigenspezifischer t-zellen

Info

Publication number
DE60334250D1
DE60334250D1 DE60334250T DE60334250T DE60334250D1 DE 60334250 D1 DE60334250 D1 DE 60334250D1 DE 60334250 T DE60334250 T DE 60334250T DE 60334250 T DE60334250 T DE 60334250T DE 60334250 D1 DE60334250 D1 DE 60334250D1
Authority
DE
Germany
Prior art keywords
specific
antigen
cells
isolation
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60334250T
Other languages
English (en)
Inventor
Mark Bonyhadi
Dale Kalamasz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
Life Technologies Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies Corp filed Critical Life Technologies Corp
Application granted granted Critical
Publication of DE60334250D1 publication Critical patent/DE60334250D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
DE60334250T 2003-05-08 2003-12-19 Erzeugung und isolierung antigenspezifischer t-zellen Expired - Lifetime DE60334250D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46912203P 2003-05-08 2003-05-08
PCT/US2003/041212 WO2004104185A1 (en) 2003-05-08 2003-12-19 Generation and isolation of antigen-specific t cells

Publications (1)

Publication Number Publication Date
DE60334250D1 true DE60334250D1 (de) 2010-10-28

Family

ID=33476667

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60334250T Expired - Lifetime DE60334250D1 (de) 2003-05-08 2003-12-19 Erzeugung und isolierung antigenspezifischer t-zellen

Country Status (11)

Country Link
US (3) US20040224402A1 (de)
EP (1) EP1623017B1 (de)
JP (2) JP2006524991A (de)
AT (1) ATE481476T1 (de)
AU (1) AU2003300359A1 (de)
CA (1) CA2525519A1 (de)
DE (1) DE60334250D1 (de)
DK (1) DK1623017T3 (de)
MX (1) MXPA05012080A (de)
TW (1) TW200502391A (de)
WO (1) WO2004104185A1 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001294859A1 (en) * 2000-09-29 2002-04-08 Molecular Probes, Inc. Modified carbocyanine dyes and their conjugates
US20090305408A1 (en) * 2005-05-11 2009-12-10 Trustees Of The University Of Pennsylvania Method for the rapid expansion of antigen specific t-cell
CN101330830B (zh) 2005-10-18 2016-01-20 国家犹太健康中心 条件无限增殖化长期干细胞和制备和使用所述细胞的方法
EP1952150B1 (de) 2005-11-23 2016-12-14 Genentech, Inc. Verfahren und zusammensetzungen in verbindung mit b-zellen-testverfahren
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
EP1840569A1 (de) * 2006-03-28 2007-10-03 Deutsches Rheuma-Forschungszentrum Berlin Verwendung des 4-1BB Rezeptors zur Identifizierung und/oder Separation aktivierter regulatorischer Th-Zellen (Treg)
US8129126B2 (en) 2006-03-24 2012-03-06 Miltenyi Biotec Gmbh Use of the 4-1BB receptor for identifying and/or separating activated regulatory Th cells (Treg)
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
KR100882445B1 (ko) * 2007-03-16 2009-02-09 울산대학교 산학협력단 항―４－１ｂｂ 항체를 이용한 항원 특이적 자가유래ｃｄ８＋ｔ 세포의 분리 및 증식 방법
US8975069B2 (en) * 2007-09-20 2015-03-10 St. Vincent's Hospital Sydney Limited Method for identifying antigen-specific regulatory T cells
US20100254958A1 (en) * 2007-10-24 2010-10-07 Anne Letsch Antigen-Specific T-Cell Preparations from Bone Marrow
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
DK2318435T3 (en) 2008-08-28 2016-02-29 Taiga Biotechnologies Inc Modulators of MYC, methods of using the same, and methods for identifying agents that modulate MYC
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CA2828401C (en) * 2011-02-28 2023-01-10 Cadila Pharmaceuticals Limited Therapeutic cancer vaccine
JP5840857B2 (ja) * 2011-04-08 2016-01-06 国立大学法人 東京大学 細胞傷害性ｔ細胞誘導用組成物
TWI490960B (zh) * 2012-01-17 2015-07-01 Chipmos Technologies Inc 半導體封裝結構及其製作方法
AU2013224027B2 (en) 2012-02-23 2019-01-24 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
CN102816734A (zh) * 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
CA2873608A1 (en) * 2012-06-11 2013-12-19 Wilson Wolf Manufacturing Corporation Improved methods of cell culture for adoptive cell therapy
EP2877189B1 (de) 2012-07-20 2021-01-06 Taiga Biotechnologies, Inc. Verbesserte rekonstitution und autorekonstitution des hämatopoietischen kompartments
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US8921055B2 (en) 2012-10-30 2014-12-30 Berkeley Lights, Inc. Detecting cells secreting a protein of interest
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
CN105431523B (zh) * 2013-03-14 2020-08-21 约翰·霍普金斯大学 纳米级人工抗原呈递细胞
WO2014145075A2 (en) 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughpout purification
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP2971287B1 (de) 2013-03-15 2019-08-14 GPB Scientific, LLC Mikrofluidische on-chip-verarbeitung von partikeln
US10124045B2 (en) 2013-11-04 2018-11-13 Uti Limited Partnership Methods and compositions for sustained immunotherapy
CN103740643B (zh) * 2014-01-21 2015-09-30 山东省齐鲁干细胞工程有限公司 一种mhc限制性杀伤t细胞的体外诱导培养方法
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
HUE056852T2 (hu) 2014-04-16 2022-03-28 Juno Therapeutics Gmbh Sejtpopuláció felszaporítására szolgáló eljárások, készletek és berendezés
CA2946552A1 (en) * 2014-04-25 2015-10-29 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
MX2016013964A (es) 2014-04-25 2017-04-06 Bluebird Bio Inc Receptores de antigenos quimericos del promotor mnd.
LT3151672T (lt) 2014-06-06 2021-02-10 Bluebird Bio, Inc. Patobulintos t ląstelių kompozicijos
WO2015191874A1 (en) * 2014-06-12 2015-12-17 Children's National Medical Center Generation of broadly-specific, virus-immune cells targeting multiple hiv antigens for preventive and therapeutic use
SG11201609707WA (en) 2014-07-01 2017-01-27 Pfizer Bispecific heterodimeric diabodies and uses thereof
US20170226216A1 (en) 2014-07-24 2017-08-10 Bluebird Bio, Inc. Bcma chimeric antigen receptors
US10780096B2 (en) * 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
ES2750725T3 (es) 2014-12-12 2020-03-26 Bluebird Bio Inc Receptores de antígeno quiméricos BCMA
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
KR20180011135A (ko) 2015-05-06 2018-01-31 유티아이 리미티드 파트너쉽 지속 치료를 위한 나노입자 조성물
GB201509202D0 (en) * 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
EP3337891B1 (de) * 2015-08-21 2023-06-07 Mayo Foundation for Medical Education and Research Verfahren und materialien zur expansion von antigenspezifischen t-zellen in kultur
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) * 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
BR112018008111A2 (pt) 2015-10-22 2018-11-06 Juno Therapeutics Gmbh métodos, kits, agentes e aparelhos para transdução
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
EP3368659A1 (de) * 2015-10-28 2018-09-05 Life Technologies AS Selektive expansion verschiedener subpopulationen von t-zellen durch veränderung der zelloberflächensignale und des signalverhältnisses
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
EP3368689B1 (de) 2015-10-28 2020-06-17 The Broad Institute, Inc. Zusammensetzungen zur modulierung von immunantworten unter verwendung von immunzellgensignaturen
CN114231486A (zh) * 2015-10-30 2022-03-25 儿童国家医疗中心 从未致敏t细胞群体产生hpv抗原特异性t细胞
US11001622B2 (en) 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
RU2021107053A (ru) * 2016-03-16 2021-08-24 Нексиммьюн, Инк. Получение антигенспецифических t-клеток
IL300730A (en) * 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
WO2018049025A2 (en) 2016-09-07 2018-03-15 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
US20190366342A1 (en) * 2016-10-24 2019-12-05 Gpb Scientific, Llc Deterministic lateral displacement in the preparation of cells and compositions for therapeutic uses
CA3042424A1 (en) 2016-11-04 2018-05-11 Bluebird Bio, Inc. Anti-bcma car t cell compositions
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
KR101862502B1 (ko) * 2017-01-02 2018-05-29 성균관대학교산학협력단 재구성 인공 암세포, 이의 제조 방법, 및 이를 포함하는 항암 조성물
EP3523332B1 (de) 2017-01-06 2021-12-29 Eutilex Co., Ltd. Anti-human-4-1-bb-antikörper und deren verwendung
WO2018183908A1 (en) 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US11913075B2 (en) 2017-04-01 2024-02-27 The Broad Institute, Inc. Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
EP3610266A4 (de) 2017-04-12 2021-04-21 Massachusetts Eye and Ear Infirmary Tumorsignatur für metastasen, zusammensetzungen von substanzen und verwendung davon
WO2018195019A1 (en) 2017-04-18 2018-10-25 The Broad Institute Inc. Compositions for detecting secretion and methods of use
KR102606210B1 (ko) 2017-04-27 2023-11-24 주노 테라퓨틱스 게엠베하 올리고머 입자 시약 및 이의 사용 방법
WO2018232195A1 (en) 2017-06-14 2018-12-20 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
DK3642331T3 (da) * 2017-06-22 2023-07-31 Neogap Therapeutics Ab Fremgangsmåde til udvidelse af T-celler og anvendelser deraf
WO2019014581A1 (en) 2017-07-14 2019-01-17 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE ACTIVITY OF A CYTOTOXIC LYMPHOCYTE
TWI832820B (zh) * 2017-07-21 2024-02-21 美商伯克利之光生命科技公司 抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
CN109641032B (zh) 2017-08-03 2022-06-24 泰加生物工艺学公司 用于治疗黑素瘤的方法和组合物
WO2019028422A1 (en) * 2017-08-04 2019-02-07 Trutino Biosciences METHODS OF ACTIVATION OF IMMUNE CELLS
CA3070575A1 (en) 2017-08-09 2019-02-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
CN111373030A (zh) 2017-09-01 2020-07-03 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
AU2018323875A1 (en) 2017-09-01 2020-04-23 Gpb Scientific, Inc. Methods for preparing therapeutically active cells using microfluidics
EP3695408A4 (de) 2017-10-02 2021-12-15 The Broad Institute, Inc. Verfahren und zusammensetzungen zur detektion und modulation einer immuntherapieresistenzgensignatur in krebs
WO2019084055A1 (en) 2017-10-23 2019-05-02 Massachusetts Institute Of Technology CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
EP3710039A4 (de) 2017-11-13 2021-08-04 The Broad Institute, Inc. Verfahren und zusammensetzungen zur behandlung von krebs durch targeting des clec2d-klrb1-wegs
US11994512B2 (en) 2018-01-04 2024-05-28 Massachusetts Institute Of Technology Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
WO2019195744A1 (en) * 2018-04-07 2019-10-10 Constant Biotechnology, Llc Glucocorticoid-resistant leukocytes and their use in the treatment of cancers and viruses
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081730A2 (en) 2018-10-16 2020-04-23 Massachusetts Institute Of Technology Methods and compositions for modulating microenvironment
EP3876979A4 (de) 2018-11-08 2022-08-24 NexImmune, Inc. T-zellzusammensetzungen mit verbesserten phänotypischen eigenschaften
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
WO2020191079A1 (en) 2019-03-18 2020-09-24 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
EP4034641A4 (de) * 2019-09-26 2024-01-03 NantBio, Inc. Primäre t-zell-expansion
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
US11865168B2 (en) 2019-12-30 2024-01-09 Massachusetts Institute Of Technology Compositions and methods for treating bacterial infections
WO2022187319A2 (en) * 2021-03-02 2022-09-09 University Of Louisville Research Foundation, Inc. Acoustofluidic separation of cells and particles via acoustic radiation force dynamics
NL2028681B1 (en) * 2021-04-02 2022-10-17 Nutcracker Therapeutics Inc Materials and methods for generating antigen-specific t cells and treating diseases
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5081029A (en) 1985-09-25 1992-01-14 Oncogen Methods of adoptive immunotherapy for treatment of aids
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US20020076407A1 (en) 1988-11-23 2002-06-20 Carl H. June Method for selectively stimulating proliferation of t cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5635697A (en) 1989-03-01 1997-06-03 Symbol Technologies, Inc. Method and apparatus for decoding two-dimensional bar code
US5763266A (en) 1989-06-15 1998-06-09 The Regents Of The University Of Michigan Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
DE3923279A1 (de) 1989-07-14 1990-01-18 Will W Prof Dr Minuth Minusheets ist ein neues produkt, um zellen in beliebigen behaeltnissen in hochdifferenzierter form auf einer moeglichst natuerlichen unterlage zu kultivieren
ATE168272T1 (de) 1989-10-27 1998-08-15 Arch Dev Corp Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
ZA91463B (en) 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
US5470730A (en) 1990-09-28 1995-11-28 Immunex Method for producing TH -independent cytotoxic T lymphocytes
US6129916A (en) 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
GB9120508D0 (en) 1991-09-26 1991-11-06 Nycomed As Diagnostic agents
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
EP0563485A1 (de) 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
US5837477A (en) 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
US5674704A (en) 1993-05-07 1997-10-07 Immunex Corporation Cytokine designated 4-IBB ligand
US7211259B1 (en) 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
ES2240962T3 (es) * 1993-06-04 2005-10-16 The United States Of America As Represented By The Secretary Of The Navy Metodo para estimular selectivamente la proliferacion de celulas t.
US5942607A (en) 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
WO1995004521A1 (en) 1993-08-10 1995-02-16 W.L. Gore & Associates, Inc. Cell encapsulating device
US5672505A (en) 1993-09-27 1997-09-30 Becton, Dickinson And Company Insert for a issue culture vessel
FR2717080B1 (fr) 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
US6008188A (en) 1994-05-06 1999-12-28 Kanebo Limited Cytokine potentiator and pharmaceutical formulation for cytokine administration
JP3680219B2 (ja) * 1994-06-28 2005-08-10 独立行政法人理化学研究所 癌細胞障害性ｔリンパ球の誘導培養方法
US5595881A (en) * 1994-08-09 1997-01-21 Anergen, Inc. Method for the detection of antigen presenting cells
GB9416657D0 (en) 1994-08-17 1994-10-12 Biocine Spa T cell activation
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
FR2729570A1 (fr) 1995-01-24 1996-07-26 Idm Immuno Designed Molecules Procede de preparation de macrophages actives, trousses et compositions pour la mise en oeuvre de ce procede
US5626561A (en) 1995-06-07 1997-05-06 Gore Hybrid Technologies, Inc. Implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US6096532A (en) 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
CA2190628C (en) 1995-06-07 2000-05-30 Mark D. Butler An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein
US5985653A (en) 1995-06-07 1999-11-16 Aastrom Biosciences, Inc. Incubator apparatus for use in a system for maintaining and growing biological cells
WO1997001304A1 (en) 1995-06-29 1997-01-16 Mallinckrodt Medical, Inc. Radiolabeled apatite particles containing a paramagnetic ion
CA2227327A1 (en) 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US20020182730A1 (en) 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5627070A (en) 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
WO1997010807A1 (en) 1995-09-22 1997-03-27 Gore Hybrid Technologies, Inc. Improved cell encapsulation device
AU1152397A (en) * 1995-12-20 1997-07-14 Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
ATE476496T1 (de) 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US5972721A (en) 1996-03-14 1999-10-26 The United States Of America As Represented By The Secretary Of The Air Force Immunomagnetic assay system for clinical diagnosis and other purposes
WO1997034618A1 (en) 1996-03-22 1997-09-25 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
WO1997044667A2 (fr) 1996-05-21 1997-11-27 Institut Pasteur Methodes d'utilisation de complexes peptide/complexe majeur d'histocompatibilite pour obtenir ou purifier des cellules t antigene-specifiques et pour stimuler des cellules t
US5962319A (en) 1997-05-19 1999-10-05 Bml, Inc. Human-Th1-specific protein, gene encoding the protein, transformants, recombinant vectors, and antibodies related to the gene
US20010031253A1 (en) 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
US5766944A (en) 1996-12-31 1998-06-16 Ruiz; Margaret Eileen T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments
JP3531712B2 (ja) 1997-06-04 2004-05-31 トヨタ自動車株式会社 車両用操舵装置
AU741130B2 (en) * 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6225118B1 (en) 1997-10-01 2001-05-01 Biocure Limited Multicellular in vitro assay of angiogenesis
EP0922758B1 (de) * 1997-10-27 2009-04-15 Rockefeller University Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
CA2309206A1 (en) * 1997-11-10 1999-05-20 Arch Development Corporation Methods for treatment of tumors and tumor cells using ex vivo activated t cells
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
DE69941150D1 (de) * 1998-05-11 2009-09-03 Miltenyi Biotec Gmbh Verfahren zur direkten auswahl von antigen-spezifischen t-zellen
FR2780891A1 (fr) 1998-07-10 2000-01-14 Univ Paris Curie Echange de lymphocytes t
WO2000023053A2 (en) * 1998-10-20 2000-04-27 Salvatore Albani Artificial antigen-specific cells and related methods
JP4688254B2 (ja) * 1999-02-09 2011-05-25 独立行政法人理化学研究所 腫瘍ワクチン
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2406864A1 (en) * 2000-02-24 2001-08-30 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030235908A1 (en) * 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
US6867041B2 (en) * 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
ES2288952T3 (es) 2000-05-11 2008-02-01 Baylor Research Institute Composiciones y metodos para producir celulas presentadoras de antigenos.
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
CN101897983A (zh) * 2001-03-30 2010-12-01 格林维尔医院系统公司 单核细胞特异性微粒运送载体
CN1541113A (zh) * 2001-04-27 2004-10-27 �Ƹ��� 利用激活的t细胞使抗原提呈细胞成熟
US20050130886A1 (en) * 2001-05-14 2005-06-16 Jan Holmgren Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
JP2004528042A (ja) 2001-06-01 2004-09-16 エクサイト セラピーズ， インコーポレイテッド Ｔ細胞誘導性組織修復および再生
DE10129912A1 (de) 2001-06-21 2003-01-02 Efmt Entwicklungs Und Forschun Nadelelektrode
US20030054544A1 (en) 2001-09-14 2003-03-20 Medcell Biologics, Inc. Oxygen enriched bioreactor and method of culturing cells
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030194395A1 (en) 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002219845A1 (en) 2001-11-19 2003-06-10 Valeocyte Therapies Llc Closed sterile system devices and methods
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy

Also Published As

Publication number Publication date
DK1623017T3 (da) 2011-01-10
MXPA05012080A (es) 2006-02-22
JP2011036263A (ja) 2011-02-24
EP1623017A4 (de) 2006-07-05
US20070212767A1 (en) 2007-09-13
JP2006524991A (ja) 2006-11-09
WO2004104185A1 (en) 2004-12-02
US20040224402A1 (en) 2004-11-11
EP1623017A1 (de) 2006-02-08
EP1623017B1 (de) 2010-09-15
CA2525519A1 (en) 2004-12-02
US7977095B2 (en) 2011-07-12
AU2003300359A1 (en) 2004-12-13
ATE481476T1 (de) 2010-10-15
TW200502391A (en) 2005-01-16
US20090137017A1 (en) 2009-05-28

Similar Documents

Publication Publication Date Title
DE60334250D1 (de) Erzeugung und isolierung antigenspezifischer t-zellen
ATE483794T1 (de) T-zellaktivierung und -expansion
MX2018010240A (es) Activacion y expansion de celulas.
MX2008004966A (en) A composition comprising a coupled enzyme system
CY1116768T1 (el) Συνθεσεις οι οποιες περιεχουν βλαστοκυτταρα θηλυκης γαμετικης σειρας και μεθοδοι χρησης αυτων
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
PH12019502485A1 (en) Expansion of yo t cells, compositions, and methods of use thereof
AU2003208567A8 (en) Methods of inducing differentiation in stem cells, methods of generating tissue using scaffold matrices derived from micro-organs and stem cells, methods of producing adult stem cells and methods of continuously generating stem cells by implantation of micro-organs as sources of stem cells
WO2008076556A3 (en) Generation of inner ear cells
ATE502997T1 (de) Oberflächenaktive peroxycarbonsäurezusammensetzungen
SG149061A1 (en) Definitive endoderm
MX2009000520A (es) Metodos para producir combustibles y solventes.
NO20065619L (no) Pyrrolidin-2-on- og piperidin-2-onderivat som 11-beta-hydroksysteroid-dehydrogenaseinhibitorer
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
AU2016204319A1 (en) Methods and compositions for producing squalene using yeast
AR038563A1 (es) Composicion de ziprasidona y controles sinteticos
NO20061845L (no) Fenyl-piperazinderivater som modulatorer for muskarine reseptorer
TW200716515A (en) Tigecycline and methods of preparing 9-aminominocycline
NO20041379L (no) Enzymatiske prosesser for fremstilling av 4-substituerte 3-hydroksysmorsyrederivater
ATE444990T1 (de) Spritzbare akustikmassen
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
BR112023018844A2 (pt) Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
ATE523188T1 (de) Parfümierungsnitrile
RS20070095A (en) Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents